iShares Biotechnology ETF (NASDAQ: IBB) Stock Competitors & Peer Comparison

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VSMPX has a market cap of 2.3T. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VSMPX trades at $345.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VSMPX's P/E ratio is 26.81. In terms of profitability, IBB's ROE is +0.00%, compared to VSMPX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VSMPX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VSMPX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VTSAX has a market cap of 2.3T. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VTSAX trades at $184.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VTSAX's P/E ratio is 26.81. In terms of profitability, IBB's ROE is +0.00%, compared to VTSAX's ROE of +0.08%. Regarding short-term risk, IBB is more volatile compared to VTSAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VTSAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VITSX has a market cap of 2.3T. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VITSX trades at $184.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VITSX's P/E ratio is -1527.25. In terms of profitability, IBB's ROE is +0.00%, compared to VITSX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VITSX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VITSX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, PMFLX has a market cap of 1.9T. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while PMFLX trades at $9.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas PMFLX's P/E ratio is N/A. In terms of profitability, IBB's ROE is +0.00%, compared to PMFLX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to PMFLX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check PMFLX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VOO has a market cap of 1.7T. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VOO trades at $703.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VOO's P/E ratio is 27.47. In terms of profitability, IBB's ROE is +0.00%, compared to VOO's ROE of +0.00%. Regarding short-term risk, IBB is more volatile compared to VOO. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VOO's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VFFSX has a market cap of 1.7T. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VFFSX trades at $376.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VFFSX's P/E ratio is 27.34. In terms of profitability, IBB's ROE is +0.00%, compared to VFFSX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VFFSX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VFFSX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VFIAX has a market cap of 1.7T. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VFIAX trades at $709.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VFIAX's P/E ratio is 27.34. In terms of profitability, IBB's ROE is +0.00%, compared to VFIAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VFIAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VFIAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VFINX has a market cap of 1.7T. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VFINX trades at $709.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VFINX's P/E ratio is 27.35. In terms of profitability, IBB's ROE is +0.00%, compared to VFINX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VFINX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VFINX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, FXAIX has a market cap of 832.5B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while FXAIX trades at $267.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas FXAIX's P/E ratio is N/A. In terms of profitability, IBB's ROE is +0.00%, compared to FXAIX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to FXAIX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check FXAIX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, SPY has a market cap of 815.6B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while SPY trades at $765.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas SPY's P/E ratio is 25.94. In terms of profitability, IBB's ROE is +0.00%, compared to SPY's ROE of +0.00%. Regarding short-term risk, IBB is more volatile compared to SPY. This indicates higher risk in terms of short-term price fluctuations for IBB.Check SPY's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VTIAX has a market cap of 666.5B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VTIAX trades at $47.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VTIAX's P/E ratio is 18.20. In terms of profitability, IBB's ROE is +0.00%, compared to VTIAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VTIAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VTIAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VTPSX has a market cap of 666.4B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VTPSX trades at $188.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VTPSX's P/E ratio is 18.19. In terms of profitability, IBB's ROE is +0.00%, compared to VTPSX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VTPSX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VTPSX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VTSNX has a market cap of 662.1B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VTSNX trades at $188.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VTSNX's P/E ratio is 18.19. In terms of profitability, IBB's ROE is +0.00%, compared to VTSNX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VTSNX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VTSNX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, QQQ has a market cap of 508.4B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while QQQ trades at $713.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas QQQ's P/E ratio is 32.76. In terms of profitability, IBB's ROE is +0.00%, compared to QQQ's ROE of +0.00%. Regarding short-term risk, IBB is more volatile compared to QQQ. This indicates higher risk in terms of short-term price fluctuations for IBB.Check QQQ's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, BMOP has a market cap of 434B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while BMOP trades at $24.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas BMOP's P/E ratio is N/A. In terms of profitability, IBB's ROE is +0.00%, compared to BMOP's ROE of +0.00%. Regarding short-term risk, IBB is more volatile compared to BMOP. This indicates higher risk in terms of short-term price fluctuations for IBB.Check BMOP's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VBMFX has a market cap of 399.1B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VBMFX trades at $9.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VBMFX's P/E ratio is N/A. In terms of profitability, IBB's ROE is +0.00%, compared to VBMFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VBMFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VBMFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VUG has a market cap of 389.4B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VUG trades at $87.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VUG's P/E ratio is 33.77. In terms of profitability, IBB's ROE is +0.00%, compared to VUG's ROE of +0.00%. Regarding short-term risk, IBB is more volatile compared to VUG. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VUG's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VIGAX has a market cap of 387.8B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VIGAX trades at $270.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VIGAX's P/E ratio is 33.63. In terms of profitability, IBB's ROE is +0.00%, compared to VIGAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VIGAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VIGAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VIGIX has a market cap of 387.8B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VIGIX trades at $270.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VIGIX's P/E ratio is 33.63. In terms of profitability, IBB's ROE is +0.00%, compared to VIGIX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VIGIX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VIGIX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, CGFAX has a market cap of 369.1B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while CGFAX trades at $86.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas CGFAX's P/E ratio is 33.36. In terms of profitability, IBB's ROE is +0.00%, compared to CGFAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to CGFAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check CGFAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, GFFFX has a market cap of 366.5B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while GFFFX trades at $87.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas GFFFX's P/E ratio is 32.35. In terms of profitability, IBB's ROE is +0.00%, compared to GFFFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to GFFFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check GFFFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, GFAFX has a market cap of 366.5B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while GFAFX trades at $87.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas GFAFX's P/E ratio is 33.12. In terms of profitability, IBB's ROE is +0.00%, compared to GFAFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to GFAFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check GFAFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VIIIX has a market cap of 357.1B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VIIIX trades at $615.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VIIIX's P/E ratio is 27.34. In terms of profitability, IBB's ROE is +0.00%, compared to VIIIX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VIIIX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VIIIX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VINIX has a market cap of 357.1B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VINIX trades at $615.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VINIX's P/E ratio is 27.34. In terms of profitability, IBB's ROE is +0.00%, compared to VINIX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VINIX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VINIX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, GAFFX has a market cap of 353.6B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while GAFFX trades at $88.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas GAFFX's P/E ratio is 33.17. In terms of profitability, IBB's ROE is +0.00%, compared to GAFFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to GAFFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check GAFFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, RGAGX has a market cap of 353.6B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while RGAGX trades at $88.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas RGAGX's P/E ratio is 33.17. In terms of profitability, IBB's ROE is +0.00%, compared to RGAGX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to RGAGX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check RGAGX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, AGTHX has a market cap of 353.5B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while AGTHX trades at $88.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas AGTHX's P/E ratio is 33.13. In terms of profitability, IBB's ROE is +0.00%, compared to AGTHX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to AGTHX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check AGTHX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VEA has a market cap of 328.1B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VEA trades at $73.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VEA's P/E ratio is 18.93. In terms of profitability, IBB's ROE is +0.00%, compared to VEA's ROE of +0.00%. Regarding short-term risk, IBB is more volatile compared to VEA. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VEA's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VTMGX has a market cap of 324.5B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VTMGX trades at $23.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VTMGX's P/E ratio is 18.73. In terms of profitability, IBB's ROE is +0.00%, compared to VTMGX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VTMGX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VTMGX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VDIPX has a market cap of 324.5B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VDIPX trades at $36.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VDIPX's P/E ratio is 18.73. In terms of profitability, IBB's ROE is +0.00%, compared to VDIPX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VDIPX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VDIPX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VTMNX has a market cap of 322.9B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VTMNX trades at $23.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VTMNX's P/E ratio is 18.73. In terms of profitability, IBB's ROE is +0.00%, compared to VTMNX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VTMNX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VTMNX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, BALFX has a market cap of 291.5B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while BALFX trades at $41.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas BALFX's P/E ratio is 26.59. In terms of profitability, IBB's ROE is +0.00%, compared to BALFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to BALFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check BALFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, AFMBX has a market cap of 291.5B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while AFMBX trades at $41.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas AFMBX's P/E ratio is 26.60. In terms of profitability, IBB's ROE is +0.00%, compared to AFMBX's ROE of +0.13%. Regarding short-term risk, IBB is more volatile compared to AFMBX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check AFMBX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, ABALX has a market cap of 291.5B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while ABALX trades at $41.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas ABALX's P/E ratio is 26.59. In terms of profitability, IBB's ROE is +0.00%, compared to ABALX's ROE of +0.13%. Regarding short-term risk, IBB is more volatile compared to ABALX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check ABALX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, CLBAX has a market cap of 287.1B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while CLBAX trades at $40.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas CLBAX's P/E ratio is 26.66. In terms of profitability, IBB's ROE is +0.00%, compared to CLBAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to CLBAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check CLBAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, AMBFX has a market cap of 286.5B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while AMBFX trades at $41.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas AMBFX's P/E ratio is 26.60. In terms of profitability, IBB's ROE is +0.00%, compared to AMBFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to AMBFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check AMBFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, RLBGX has a market cap of 286.4B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while RLBGX trades at $41.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas RLBGX's P/E ratio is 26.60. In terms of profitability, IBB's ROE is +0.00%, compared to RLBGX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to RLBGX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check RLBGX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, RGABX has a market cap of 269.1B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while RGABX trades at $76.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas RGABX's P/E ratio is 32.14. In terms of profitability, IBB's ROE is +0.00%, compared to RGABX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to RGABX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check RGABX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, RGAAX has a market cap of 264.1B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while RGAAX trades at $75.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas RGAAX's P/E ratio is 32.15. In terms of profitability, IBB's ROE is +0.00%, compared to RGAAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to RGAAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check RGAAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, FCTDX has a market cap of 262.9B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while FCTDX trades at $22.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas FCTDX's P/E ratio is N/A. In terms of profitability, IBB's ROE is +0.00%, compared to FCTDX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to FCTDX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check FCTDX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VTV has a market cap of 261.7B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VTV trades at $226.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VTV's P/E ratio is 22.39. In terms of profitability, IBB's ROE is +0.00%, compared to VTV's ROE of +0.00%. Regarding short-term risk, IBB is more volatile compared to VTV. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VTV's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VVIAX has a market cap of 260.5B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VVIAX trades at $88.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VVIAX's P/E ratio is 22.26. In terms of profitability, IBB's ROE is +0.00%, compared to VVIAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VVIAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VVIAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, GFACX has a market cap of 257.2B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while GFACX trades at $73.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas GFACX's P/E ratio is 33.03. In terms of profitability, IBB's ROE is +0.00%, compared to GFACX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to GFACX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check GFACX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, SWVXX has a market cap of 245.3B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while SWVXX trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas SWVXX's P/E ratio is N/A. In terms of profitability, IBB's ROE is +0.00%, compared to SWVXX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to SWVXX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check SWVXX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, PIMIX has a market cap of 231.8B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while PIMIX trades at $10.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas PIMIX's P/E ratio is N/A. In terms of profitability, IBB's ROE is +0.00%, compared to PIMIX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to PIMIX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check PIMIX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, PONPX has a market cap of 231.8B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while PONPX trades at $10.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas PONPX's P/E ratio is N/A. In terms of profitability, IBB's ROE is +0.00%, compared to PONPX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to PONPX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check PONPX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VO has a market cap of 229.7B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VO trades at $82.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VO's P/E ratio is 24.57. In terms of profitability, IBB's ROE is +0.00%, compared to VO's ROE of +0.00%. Regarding short-term risk, IBB is more volatile compared to VO. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VO's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VMCPX has a market cap of 228.3B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VMCPX trades at $447.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VMCPX's P/E ratio is 24.43. In terms of profitability, IBB's ROE is +0.00%, compared to VMCPX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VMCPX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VMCPX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VIMAX has a market cap of 228.3B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VIMAX trades at $411.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VIMAX's P/E ratio is 24.43. In terms of profitability, IBB's ROE is +0.00%, compared to VIMAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VIMAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VIMAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VMCIX has a market cap of 228.3B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VMCIX trades at $90.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VMCIX's P/E ratio is 24.43. In terms of profitability, IBB's ROE is +0.00%, compared to VMCIX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VMCIX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VMCIX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, ODIDX has a market cap of 213.2B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while ODIDX trades at $8.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas ODIDX's P/E ratio is N/A. In terms of profitability, IBB's ROE is +0.00%, compared to ODIDX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to ODIDX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check ODIDX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VB has a market cap of 194.8B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VB trades at $304.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VB's P/E ratio is 22.29. In terms of profitability, IBB's ROE is +0.00%, compared to VB's ROE of +0.00%. Regarding short-term risk, IBB is more volatile compared to VB. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VB's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VSMAX has a market cap of 193.4B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VSMAX trades at $146.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VSMAX's P/E ratio is 22.13. In terms of profitability, IBB's ROE is +0.00%, compared to VSMAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VSMAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VSMAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VSCIX has a market cap of 193.4B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VSCIX trades at $146.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VSCIX's P/E ratio is 22.13. In terms of profitability, IBB's ROE is +0.00%, compared to VSCIX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VSCIX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VSCIX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, APO-PA has a market cap of 190.8B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while APO-PA trades at $170.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas APO-PA's P/E ratio is 20.43. In terms of profitability, IBB's ROE is +0.00%, compared to APO-PA's ROE of +0.09%. Regarding short-term risk, IBB is more volatile compared to APO-PA. This indicates higher risk in terms of short-term price fluctuations for IBB.Check APO-PA's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, RICBX has a market cap of 185.9B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while RICBX trades at $68.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas RICBX's P/E ratio is 28.64. In terms of profitability, IBB's ROE is +0.00%, compared to RICBX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to RICBX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check RICBX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, AICCX has a market cap of 185.9B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while AICCX trades at $67.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas AICCX's P/E ratio is 28.64. In terms of profitability, IBB's ROE is +0.00%, compared to AICCX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to AICCX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check AICCX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, FCNKX has a market cap of 185B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while FCNKX trades at $26.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas FCNKX's P/E ratio is N/A. In terms of profitability, IBB's ROE is +0.00%, compared to FCNKX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to FCNKX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check FCNKX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, FCNTX has a market cap of 185B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while FCNTX trades at $26.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas FCNTX's P/E ratio is N/A. In terms of profitability, IBB's ROE is +0.00%, compared to FCNTX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to FCNTX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check FCNTX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, FUNFX has a market cap of 182.7B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while FUNFX trades at $103.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas FUNFX's P/E ratio is 28.88. In terms of profitability, IBB's ROE is +0.00%, compared to FUNFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to FUNFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check FUNFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, FINFX has a market cap of 182.7B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while FINFX trades at $103.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas FINFX's P/E ratio is 28.87. In terms of profitability, IBB's ROE is +0.00%, compared to FINFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to FINFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check FINFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, ANCFX has a market cap of 182.7B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while ANCFX trades at $103.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas ANCFX's P/E ratio is 28.87. In terms of profitability, IBB's ROE is +0.00%, compared to ANCFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to ANCFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check ANCFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, CICAX has a market cap of 181.6B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while CICAX trades at $68.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas CICAX's P/E ratio is 28.88. In terms of profitability, IBB's ROE is +0.00%, compared to CICAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to CICAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check CICAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, FFICX has a market cap of 180.3B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while FFICX trades at $69.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas FFICX's P/E ratio is 28.69. In terms of profitability, IBB's ROE is +0.00%, compared to FFICX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to FFICX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check FFICX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, AICFX has a market cap of 180.3B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while AICFX trades at $68.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas AICFX's P/E ratio is 28.67. In terms of profitability, IBB's ROE is +0.00%, compared to AICFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to AICFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check AICFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, AIVSX has a market cap of 180.3B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while AIVSX trades at $69.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas AIVSX's P/E ratio is 28.68. In terms of profitability, IBB's ROE is +0.00%, compared to AIVSX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to AIVSX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check AIVSX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, RICAX has a market cap of 180.2B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while RICAX trades at $68.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas RICAX's P/E ratio is 28.64. In terms of profitability, IBB's ROE is +0.00%, compared to RICAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to RICAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check RICAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, BLK has a market cap of 179.2B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while BLK trades at $1,156.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas BLK's P/E ratio is 22.60. In terms of profitability, IBB's ROE is +0.00%, compared to BLK's ROE of +0.12%. Regarding short-term risk, IBB is more volatile compared to BLK. This indicates higher risk in terms of short-term price fluctuations for IBB.Check BLK's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, CFNAX has a market cap of 178.3B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while CFNAX trades at $103.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas CFNAX's P/E ratio is 28.91. In terms of profitability, IBB's ROE is +0.00%, compared to CFNAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to CFNAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check CFNAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, AFIFX has a market cap of 178B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while AFIFX trades at $103.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas AFIFX's P/E ratio is 28.86. In terms of profitability, IBB's ROE is +0.00%, compared to AFIFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to AFIFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check AFIFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, RFNCX has a market cap of 178B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while RFNCX trades at $103.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas RFNCX's P/E ratio is 28.85. In terms of profitability, IBB's ROE is +0.00%, compared to RFNCX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to RFNCX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check RFNCX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, FNPFX has a market cap of 173.8B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while FNPFX trades at $76.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas FNPFX's P/E ratio is 27.33. In terms of profitability, IBB's ROE is +0.00%, compared to FNPFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to FNPFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check FNPFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, NPFFX has a market cap of 173.7B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while NPFFX trades at $75.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas NPFFX's P/E ratio is 27.30. In terms of profitability, IBB's ROE is +0.00%, compared to NPFFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to NPFFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check NPFFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, BX has a market cap of 170.8B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while BX trades at $143.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas BX's P/E ratio is 24.21. In terms of profitability, IBB's ROE is +0.00%, compared to BX's ROE of +0.41%. Regarding short-term risk, IBB is less volatile compared to BX. This indicates lower risk in terms of short-term price fluctuations for IBB.Check BX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, RNPGX has a market cap of 169.9B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while RNPGX trades at $76.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas RNPGX's P/E ratio is 27.33. In terms of profitability, IBB's ROE is +0.00%, compared to RNPGX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to RNPGX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check RNPGX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, ANWPX has a market cap of 169.9B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while ANWPX trades at $76.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas ANWPX's P/E ratio is 27.31. In terms of profitability, IBB's ROE is +0.00%, compared to ANWPX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to ANWPX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check ANWPX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, RNPCX has a market cap of 169.9B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while RNPCX trades at $73.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas RNPCX's P/E ratio is 27.27. In terms of profitability, IBB's ROE is +0.00%, compared to RNPCX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to RNPCX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check RNPCX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, SPCK has a market cap of 168B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while SPCK trades at $22.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas SPCK's P/E ratio is -20.16. In terms of profitability, IBB's ROE is +0.00%, compared to SPCK's ROE of +0.00%. Regarding short-term risk, IBB is more volatile compared to SPCK. This indicates higher risk in terms of short-term price fluctuations for IBB.Check SPCK's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VEMRX has a market cap of 166.9B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VEMRX trades at $126.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VEMRX's P/E ratio is 16.88. In terms of profitability, IBB's ROE is +0.00%, compared to VEMRX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VEMRX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VEMRX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VEMAX has a market cap of 165.2B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VEMAX trades at $50.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VEMAX's P/E ratio is 16.88. In terms of profitability, IBB's ROE is +0.00%, compared to VEMAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VEMAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VEMAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, WGIFX has a market cap of 157.2B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while WGIFX trades at $82.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas WGIFX's P/E ratio is 25.44. In terms of profitability, IBB's ROE is +0.00%, compared to WGIFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to WGIFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check WGIFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, FPMAX has a market cap of 154.3B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while FPMAX trades at $10.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas FPMAX's P/E ratio is N/A. In terms of profitability, IBB's ROE is +0.00%, compared to FPMAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to FPMAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check FPMAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, AWSHX has a market cap of 154.2B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while AWSHX trades at $69.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas AWSHX's P/E ratio is 26.58. In terms of profitability, IBB's ROE is +0.00%, compared to AWSHX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to AWSHX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check AWSHX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, RWMFX has a market cap of 154.1B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while RWMFX trades at $68.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas RWMFX's P/E ratio is 26.59. In terms of profitability, IBB's ROE is +0.00%, compared to RWMFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to RWMFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check RWMFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, FWMIX has a market cap of 154.1B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while FWMIX trades at $68.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas FWMIX's P/E ratio is 26.59. In terms of profitability, IBB's ROE is +0.00%, compared to FWMIX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to FWMIX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check FWMIX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, CWMAX has a market cap of 153.6B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while CWMAX trades at $68.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas CWMAX's P/E ratio is 26.58. In terms of profitability, IBB's ROE is +0.00%, compared to CWMAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to CWMAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check CWMAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, WSHFX has a market cap of 153.2B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while WSHFX trades at $68.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas WSHFX's P/E ratio is 26.57. In terms of profitability, IBB's ROE is +0.00%, compared to WSHFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to WSHFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check WSHFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, WSHCX has a market cap of 150.6B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while WSHCX trades at $67.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas WSHCX's P/E ratio is 26.53. In terms of profitability, IBB's ROE is +0.00%, compared to WSHCX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to WSHCX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check WSHCX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, RWMBX has a market cap of 150.1B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while RWMBX trades at $67.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas RWMBX's P/E ratio is 26.52. In terms of profitability, IBB's ROE is +0.00%, compared to RWMBX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to RWMBX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check RWMBX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, GLD has a market cap of 149.4B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while GLD trades at $423.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas GLD's P/E ratio is 232664.84. In terms of profitability, IBB's ROE is +0.00%, compared to GLD's ROE of +0.00%. Regarding short-term risk, IBB is more volatile compared to GLD. This indicates higher risk in terms of short-term price fluctuations for IBB.Check GLD's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, SWPPX has a market cap of 147.1B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while SWPPX trades at $19.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas SWPPX's P/E ratio is 27.38. In terms of profitability, IBB's ROE is +0.00%, compared to SWPPX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to SWPPX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check SWPPX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, FIFAX has a market cap of 146.7B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while FIFAX trades at $28.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas FIFAX's P/E ratio is 20.00. In terms of profitability, IBB's ROE is +0.00%, compared to FIFAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to FIFAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check FIFAX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, RERGX has a market cap of 144.5B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while RERGX trades at $65.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas RERGX's P/E ratio is 19.72. In terms of profitability, IBB's ROE is +0.00%, compared to RERGX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to RERGX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check RERGX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, AEGFX has a market cap of 144.5B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while AEGFX trades at $64.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas AEGFX's P/E ratio is 19.68. In terms of profitability, IBB's ROE is +0.00%, compared to AEGFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to AEGFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check AEGFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, RERHX has a market cap of 142.6B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while RERHX trades at $64.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas RERHX's P/E ratio is 19.69. In terms of profitability, IBB's ROE is +0.00%, compared to RERHX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to RERHX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check RERHX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, AEPFX has a market cap of 142.6B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while AEPFX trades at $65.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas AEPFX's P/E ratio is 19.71. In terms of profitability, IBB's ROE is +0.00%, compared to AEPFX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to AEPFX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check AEPFX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, AEPGX has a market cap of 142.6B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while AEPGX trades at $65.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas AEPGX's P/E ratio is 19.69. In terms of profitability, IBB's ROE is +0.00%, compared to AEPGX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to AEPGX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check AEPGX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, NAESX has a market cap of 139.7B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while NAESX trades at $146.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas NAESX's P/E ratio is 22.13. In terms of profitability, IBB's ROE is +0.00%, compared to NAESX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to NAESX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check NAESX's competition here

iShares Biotechnology ETF (NASDAQ: IBB) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBB stands at 10.5B. In comparison, VITAX has a market cap of 139.6B. Regarding current trading prices, IBB is priced at $213.56 on the NASDAQ, while VITAX trades at $485.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBB currently has a P/E ratio of 27.64, whereas VITAX's P/E ratio is 35.55. In terms of profitability, IBB's ROE is +0.00%, compared to VITAX's ROE of N/A. Regarding short-term risk, IBB is more volatile compared to VITAX. This indicates higher risk in terms of short-term price fluctuations for IBB.Check VITAX's competition here